Author: John A. Wagner, MD, PhD on July 21, 2022 
Clinical and Translational Science (CTS), an official journal of the American Society for Clinical Pharmacology and Therapeutics, has refreshed and refined our aim and scope, aligned with the translational approach of the National Center for Advancing Translational Sciences (NCATS) as well as Christopher P. Austin’s recent CTS review, “Opportunities and challenges in translational science.”
Our aim is to improve human health by highlighting original translational science research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease. Our scope reflects the multi-faceted discipline of translational science across the spectrum of translation. CTS welcomes high quality, scientifically sound, original manuscripts across therapeutic areas and within translational science domains, including basic translational research, preclinical research connecting the basic science of disease with human medicine and therapeutics, clinical research, clinical implementation, and public health research focused on health outcomes and disease at the population level as well as reverse translation and evaluation of all categories of biomarkers, including analytical validation, clinical validation, and qualification across modalities (e.g., molecular, histology, imaging, physiology, digital).
CTS is also interested in hypothesis-generating studies as well as negative results of studies answering important scientific questions executed with high quality experimental design and rigorous data analysis, which disproves a hypothesis or produces negative results. Additionally, CTS includes topical reviews, mini-reviews, tutorials, position papers, and may call for special collections that focus on current topics in translational science.
The CTS editorial team invites you to submit your translational research to CTS, whether your work highlights original translational science research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease or is a bold new component of a future.
The comment feature is locked by administrator.